The Brii Biosciences-backed lung diease drug developer will use the proceeds from the offering to advance its epetraborole drug candidate and expand into Japan.
AN2 Therapeutics, a US-based lung disease therapy developer backed by drug producer Brii Biosciences, has filed to raise up to $75m in an initial public offering on the Nasdaq Global Market.
Founded in 2018, AN2 is developing therapeutics for rare and chronic infectious diseases including non-tuberculous mycobacterial (NTM) lung illness. Its lead drug candidate is a once-daily oral medication called epetraborole which it licensed from Anacor Pharmaceuticals, a biopharmaceutical company since acquired by pharmaceutical firm Pfizer.
The company intends…
